Abstract
BackgroundTriple therapy (telaprevir/pegylated interferon/ribavirin), is the treatment of choice in patients with genotype 1 chronic hepatitis C virus (HCV). Triple therapy (TT) requires active participation by the hospital pharmacist, because...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Hospital Pharmacy: Science and Practice
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
